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Abstract
Background: Adenocarcinoma of the pancreas is one of the most aggressive cancer diseases affecting the human
body. The oncogenic potential of this type of cancer is mainly characterized by its extreme growth rate triggered
by the activation of signaling cascades. Modern oncological treatment strategies aim at efficiently modulating
specific signaling and transcriptional pathways. Recently, anti-tumoral potential has been proven for several
substances that are not primarily used in cancer treatment. In some tumor entities, for example, administration of
glutamate antagonists inhibits cell proliferation, cell cycle arrest, and finally cell death.
To attain endogenic proof of NMDA receptor type expression in the pancreatic cancer cell lines PaTu8988t and
Panc-1 and to investigate the impact of ketamine, s-ketamine, and the NMDA receptor antagonist MK 801 on
proliferation, apoptosis, and necrosis in pancreatic carcinoma.
Methods: Cell proliferation was measured by means of the ELISA BrdU assay, and the apoptosis rate was analyzed
by annexin V staining. Immunoblotting were also used.
Results: The NMDA receptor type R2a was expressed in both pancreatic carcinoma cell lines. Furthermore,
ketamine, s-ketamine, and MK 801 significantly inhibited proliferation and apoptosis.
Conclusions: In this study, we showed the expression of the NMDA receptor type R2a in pancreatic cancer cells.
The NMDA antagonists ketamine, s-ketamine, and MK 801 inhibited cell proliferation and cell death. Further clinical
studies are warranted to identify the impact of these agents on the treatment of cancer patients.
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Background
Malignant cancer diseases are one of the major causes of
death worldwide. In 2008, malignant tumors resulted in
about 7.6 million deaths (approximately 13 % of all
causes of death), and this figure is expected to rise to
over 13 million deaths per year in 2030 [1]. One type of
malignant tumor that nearly always results in death be-
cause of its aggressive behavior is adenocarcinoma of the
pancreas [2]. Due to the lack of characteristic early
symptoms and suitable screening tests, 50 % of patients
are already affected by infiltrated lymph nodes at the
time of diagnosis. According to current knowledge, this
tumor stage is no longer considered curable [3]. Most of
these tumors are classified as surgically incurable and
have a poor prognosis for treatment [4]. Thus, the 5-
year survival rate of less than 5 % is particularly unfavor-
able [5]. Apart from surgery, alternative and curatively
successful treatment options are rare because pancreatic
carcinoma is extremely resistant to radiation treatment
and chemotherapy [6]. Recently, however, anti-tumoral
potential has been proven in several substances that are
not primarily used in cancer treatment, and these find-
ings may open up new therapeutic options in the future
[7]. Glutamate antagonists, for example, inhibit cell pro-
liferation [8–10] and induce cell cycle arrest [11] and
cell death [12] in some tumor entities. MK 801 was used
for this purpose in many preclinical studies [13], but the
psychotropic effects of this glutamate antagonist signifi-
cantly restrict its clinical application.
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Ketamine, one of the most common N-methyl-D-
aspartate (NMDA) receptor antagonists used in clinical
practice, was first described in the literature in 1965 and
approved as an anesthetic for clinical use in 1970 [14].
Ketamine is a racemic derivative consisting of the two
enantiomers s(+)ketamine and r(−)ketamine. S(+)keta-
mine has a four times higher binding capacity at the
phencyclidine binding site of the NDMA receptor than
r(−)ketamine [15]. Additionally, ketamine interacts with
opioid, monaminic, and muscarinic receptors as well as
with voltage-gated Ca2+ channels and the AMPA recep-
tor [16]. However, the effect of ketamine fundamentally
differs from that of other anesthetic drugs. Because even
subnarcotic doses of ketamine result in pronounced an-
algesia [17], this NMDA receptor antagonist is often
used in preventive pain management but also in cancer
pain therapy in patients with opiate-resistant pain [18].
Aim of this study was to scan NMDA receptor type
expression in pancreatic cancer cells. A further objective
was to investigate the effects of ketamine, s-ketamine,
and the uncompetitive NMDA receptor antagonist MK




The human pancreatic adenocarcinoma cell lines
PaTu8988t and Panc-1 were obtained from Professor
Ellenrieder (Philipps University of Marburg, Germany).
PaTu8988t and Panc-1 cells were maintained in Dulbecco’s
modified Eagle’s medium (Sigma-Aldrich, Steinsheim,
Germany) supplemented with 10 % fetal calf serum
(FCS) (Sigma-Aldrich) and 5 % Myco Zap (Lonza Ver-
viers SPRL, Verviers, Belgium). Cells were cultured at
37 °C in humidified CO2 atmosphere (5 %) and main-
tained in monolayer culture. Experiments were done
with cells at ~70-80 % confluence.
Antibodies and reagents
Ketamine, s-ketamine, and MK 801 were purchased from
Sigma-Aldrich. Final concentrations were achieved by di-
luting drugs in standard growth media. All solutions were
prepared freshly prior to use. For immunoblotting, mem-
branes were probed with antibodies against NMDA R1,
NMDA R2a, NMDA R2b (BD Bioscience, Heidelberg,
Germany), and ß-Actin (Sigma-Aldrich).
Subcellular fractionation and immunoblotting
Cells were washed twice with cold DPBS and collected
by centrifugation at 4000 rpm at 4 °C for 10 min. Lysates
were then resuspended in RIPAE-Buffer (5 mL Triton
X100, 190 mg EDTA, 0.5 g SDS, 2.5 g Deoxycolid Acid,
500 mL DPBS, proteinase inhibitors) for 15 min and
centrifuged at 13.000 rpm for 30 min. Supernatants were
transferred to new cups and incubated on ice. 30 μg of
total lysates were analyzed by SDS-PAGE and blotted onto
nitrocellulose. Upon protein extraction and gel transfer,
membranes were washed in TBS washing buffer and incu-
bated with peroxidase-conjugated secondary antibodies.
Immunoreactive proteins were visualized by means of an
enhanced chemiluminescence detection system (Western
Blotting Detection Reagent, GE Healthcare).
Cell proliferation
The quantification of cell proliferation was based on the
measurement of BrdU incorporation during DNA synthe-
sis. The test was done according to the manufactures
protocol (Cell proliferation ELISA BrdU, Roche applied
science, Mannheim Germany). In brief, cells were incu-
bated with 100 μL of the test compounds for 48 h (0.1-
1000 μM ketamine, s-ketamine, and MK 801). After 32 h
incubation, cells were additionally treated with BrdU la-
beling solution for the last 16 h. The culture medium was
removed, cells were fixed, and DNA was denatured. After-
wards, cells were incubated with Anti-BrdU-POD solution
for 90 min, and antibody conjugates were removed in
three washing cycles. Immune complexes were detected
by means of TMB substrate for 15 min and quantified by
measuring the absorbance at 405 nm and 490 nm. All
tests were done in duplicates with eight wells per treat-
ment group and repeated at least twice.
Apoptosis analysis
Apoptosis assays by annexin V staining were conducted ac-
cording to the manufacturer’s instructions (BD Pharming).
In brief, PaTu8988t and Panc-1 cells were incubated with
test reagents (10 μM ketamine, 10 μM s-ketamine, and
10 μM MK 801). Staurosporine was used for positive con-
trol and standard growth medium for negative control.
After 0 h, 3 h, 6 h, 16 h, or 24 h incubation time, super-
natant was decanted from the cells to preserve floating
cells. Adherent cells were rinsed with warm PBS (Sigma
Aldrich) and harvested by standard trypsinization. After-
wards, harvested and floating cells were mixed, washed,
and resuspended in binding buffer at a final concentration
of 106 cells/ml. 100 μL of the cell suspension containing
105 cells was resuspended in 5 μL of FITC Annexin plus
5 μL of propidium iodide, followed by 15 min incubation at
room temperature protected from light. Cells were washed
and resuspended with 400 μL of binding buffer. Finally,
cells were analyzed by flow cytometry using FACS Calibur
(BD Bioscience) and Cellquest Pro software (BD Bio-
science). All tests were done in duplicates and repeated
twice.
Statistical analysis
Data are presented as mean ± SD. The non-parametric
Mann–Whitney-U-Test was used for statistical evaluation
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of the data. P values < 0.05 were considered significant.
IBM SPSS Statistics (Vs. 20; IBM New York, US) and
Excel Vs. 2010 (Microsoft, Redmond, USA) packages were
employed for statistical analysis.
Results
Endogenic expression of NMDA receptors in pancreatic
cancer cells
The first aim was to obtain evidence for the actual ex-
pression of the NMDA receptor types R1, R2a, and R2b
in pancreatic cancer cells (Fig. 1). Expression of the
NMDA receptor types R1 and R2b could not be proven
in any of the cell lines used (row 1 + 3). In contrast, the
NMDA receptor type R2a was expressed in the pancre-
atic cancer cell lines PaTu8988t and Panc-1 (row 2). As
control, endogenic expression of ß-Actin was shown
(row 4).
Cell proliferation behavior
PaTu8988t and Panc-1 pancreatic cancer cells were
stimulated with 0.1 μM, 1 μM, 10 μM, 100 μM, and
1000 μM ketamine (a), s-ketamine (b), or MK 801 (c)
each for 48 h. As a result, proliferation was significantly
inhibited in both cell lines at concentrations of 1000 μM
ketamine, 1000 μM s-ketamine, and 1000 μM MK 801
(Fig. 2). 1 μM MK 801 yielded a slight but significant
increase in proliferation by 5 % +/− 24 % in PaTu8988t
cells compared to the untreated control group (Fig. 2c).
A further increase in proliferation of 23 % +/− 15 % was
found in Panc-1 pancreatic cancer cells at a concentra-
tion of 0.1 μM ketamine compared to the untreated con-
trol group (Fig. 2a).
Analysis of apoptosis and necrosis
The annexin V staining apoptosis assay was used to de-
termine whether stimulation with ketamine, s-ketamine,
or MK 801 incurred apoptosis or necrosis. Incubating s-
ketamine in the pancreatic cancer cells PaTu8988t for
3 h (Fig. 3b) reduced the apoptotic cell fraction phase to
62 % +/− 27 % compared to the untreated samples.
Ketamine and MK 801 did not induce any changes in
cell death behavior.
In contrast to the untreated control samples in the cell
line Panc-1, the apoptosis rate (Figs. 4) was significantly
reduced after 24 h incubation with ketamine (a) (65 %
+/− 17 %) and s-ketamine (b) (68 % +/− 24 %) as well as
after 16 h incubation with MK 801 (c) (67 % +/− 23 %).
In contrast, the necrosis rate increased after 16 h
stimulation with ketamine and, in vital cells, after 24 h
incubation with ketamine (Fig. 4a).
Stimulation with s-ketamine (Fig. 4b) significantly in-
creased necrosis after 6 h, 16 h, and 24 h, and stimula-
tion with MK 801 (Fig. 4c) significantly increased the
vital cells.
No other significant changes in the apoptosis rate were
observed during the other timeframes. Staurosporine, an
often employed method for inducing apoptosis, was used
as a positive control for the testing procedure and in-
duced significant apoptosis in the pancreatic cancer cells
(Figure not shown).
Discussion
Three types of ionotropic glutamate receptors are known
that are termed according to their prototypic receptor-
agonist N-methyl-D-aspartate (NMDA), 2-amino-3-(3-
hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA),
and kainate (KA) [19]. N-methyl-D-aspartate (NMDA),
which belongs to the family of ionotropic glutamate recep-
tors, is vital for the transmission of stimulating signals be-
tween nerve cells [20]. Physiologically, NMDA plays a
major role in processes of synaptic plasticity and memory
formation [21]. NMDA is also important during various-
neurolopathological conditions, such as Alzheimer disease,
Parkinson disease, multiple sclerosis, epilepsy, or depres-
sion [22]. For many years, NMDA receptor expression
was associated with the central nervous system, but recent
trials have shown that functional NMDA receptors may
also be expressed in tumors[23]. The receptor type has
already been successfully proven in various tumor cell
lines, for instance, in neuronal tumors (astrocytoma,
Fig. 1 Immunblotting and proof of the endogenic expression of the
NMDA receptor types R1, R2a, R2b, and ß-Actin in PaTu8988t and
Panc-1 pancreatic cancer cells
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glioma, and neuroblastoma), rhabdomyosarcoma, medullo-
blastoma, thyroid carcinoma, lung carcinoma, colon car-
cinoma, and mamma carcinoma as well as in T-cell
chronic lymphocytic leukemia, multiple myeloma [23],
and carcinoma of the larynx [25].
In the present study, NMDA receptor type R2a expres-
sion could be detected in the pancreatic carcinoma cells
PaTu8988t and Panc-1. However, the influence of the
NMDA receptor on the oncogenic behavior of cancer
cells has not yet been sufficiently investigated. Kalariti et
al. assumed in 2005 that the NMDA receptor may be a
critical factor in tumor development, tumor growth, and
the metastasis of tumor cells [26]. Furthermore, NMDA
receptor expression in prostate carcinoma was increased
in comparison to healthy prostate tissue [27]. Watanabe
et al. showed in 2008 that the NMDA receptor subunit
Figs. 2 The effects of ketamine (a), s-ketamine (b), and MK 801 (c) on cell proliferation in PaTu8988t and Panc-1 pancreatic carcinoma cell lines in
vitro. Cell proliferation was quantified by measuring BrdU incorporation. (*) indicate statistical significance at p < 0.05 compared to
untreated control
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R2a plays an important role in regulating proliferation
by accelerating the cell cycle in cell lines of gastric can-
cer [28]. In other clinical studies, blocking of the NMDA
receptor subunit R2a inhibited the proliferation of can-
cer cells of lung carcinoma and esophagus carcinoma
[29, 30].
The next step in our trial was therefore to investigate
the impact of ketamine, s-ketamine, and the noncompet-
itive NMDA receptor antagonist MK 801 on the pro-
liferation, apoptosis, and necrosis of pancreatic cancer
cells.
In their study including 31 patients, Idyall et al. investi-
gated the clinical effects of intravenously injected ketamine
and its pharmacokinetics. After the injection of 2 mg/kg of
ketamine iv, plasma concentration was analyzed by means
of gas–liquid chromatography. The average maintenance
dose was 41 μg/kg/min, which corresponded to a plasma
concentration of 9.3 μM [31].
As our aim was to investigate the direct effect of keta-
mine, s-ketamine and MK 801 on cancer cell lines, we
used concentrations similar to clinically achievable plasma
concentrations (0,1 μM – 1000 μM).
We found that incubation with high-dose ketamine, s-
ketamine, and MK 801 significantly inhibited cell prolif-
eration in all cell lines. Lee et al. described in 2009 that
administration of s-ketamine induced mitochondrial
apoptosis in hepatocellular carcinoma [12]. In breast
cancer cells, however, the anti-apoptotic protein BCL-2
was up-regulated, and both cell invasion and the prolif-
eration rate were increased [32]. In our study, all test
substances also decreased the rate of apoptosis in pan-
creatic cancer cells. The main effect of ketamine, s-
ketamine, and MK 801 is based on the noncompetitive
blockade of the NMDA receptor complex. During this
process, ketamine binds to the phencyclidine (PCP)
binding site inside the NMDA channel, inhibiting the ef-
fectiveness of NMDA antagonists, such as glutamate,
NMDA, or glycine [33].
Tumor progression including the proliferation and
apoptosis of cells is regulated by various signaling cas-
cades. As a first messenger, calcium is of vital import-
ance in this respect [34]. NMDA receptor activation
increases the intracellular calcium concentration and ac-
tivates Ca2+-dependent systolic guanylate cyclase [35].
Figs. 3 and 4 The effects of ketamine (a), s-ketamine (b), and MK 801 (c) on apoptosis in PaTu8988t (Figs. 3) and Panc-1 (Figs. 4) pancreatic car-
cinoma cell lines in vitro. For apoptosis analysis, cancer cells were stained with Annexin V. (*) indicate statistical significance at p < 0.05 compared
to untreated control
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Calcium influx into cell cytosol results in the calcium-
dependent activation of a secondary messenger, which
may again activate proteins of various types − amongst
others transcription factors − that significantly influence
the further behavior of tumor cells [36].
Conclusions
In this study, we showed the expression of the NMDA
receptor type R2a in pancreatic cancer cells. The NMDA
antagonists ketamine, s-ketamine, and MK 801 inhibited
cell proliferation and cell death.
The perioperative period is assumed to be a critical time
with regard to cancer dissemination and metastasis [37],
probably due to a fatal combination of several factors: sur-
gical manipulation results in the release of cancer cells
into circulation, growth factor levels are excessively en-
hanced during the wound healing process, and anticancer
immune surveillance is impaired by perioperative im-
munosuppression [38].
Results of several preclinical and clinical studies have
indicated that the selection of special anesthesia tech-
niques, such as regional anesthesia, may affect cancer re-
currence after surgery [39, 40] . Several well-established
anesthetic and analgesic agents have been tested for
their anticancer potency [41–45].
Modern treatment strategies of cancer diseases aim at
efficaciously modulating specific signaling and trans-
criptional pathways (for instance, VEGF antibodies [45],
tyrosine kinase inhibitors for treating chronic lymphatic
leukemia [46], or EGFR antibodies for treating advanced
colon carcinoma) [47]. The therapeutic potential of inhi-
biting Ca2+ channels or Ca2+-regulating enzymes in tumor
cells has been debated for many years [48]. The basis and
prerequisite of such new therapeutic approaches to a ‘tar-
geted therapy’ necessitates comprehensive knowledge of
the particular carcinogenesis. For this reason, further clin-
ical studies are required to identify the underlying mecha-
nisms. The identification and characterization of cellular
receptors as well as their extracellular activators will help
establish new therapeutic options in the treatment of ag-
gressive pancreatic carcinoma.
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